Nykredit A S Purchases New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Nykredit A S acquired a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 51,208 shares of the biopharmaceutical company’s stock, valued at approximately $15,415,000.

Several other large investors also recently bought and sold shares of ALNY. MV Capital Management Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $25,000. HM Payson & Co. purchased a new position in Alnylam Pharmaceuticals in the 4th quarter valued at $27,000. Golden State Wealth Management LLC lifted its holdings in Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 36 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth $29,000. Finally, Manchester Capital Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 600.0% during the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 72 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ:ALNY opened at $266.11 on Friday. The business has a 50-day moving average price of $259.25 and a 200 day moving average price of $291.61. The company has a market capitalization of $35.61 billion, a price-to-earnings ratio of 49.46 and a beta of 0.31. Alnylam Pharmaceuticals, Inc. has a 12-month low of $197.81 and a 12-month high of $495.55. The company has a current ratio of 3.05, a quick ratio of 2.99 and a debt-to-equity ratio of 0.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.63 by $0.21. The firm had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.32 billion. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.Alnylam Pharmaceuticals’s revenue was up 66.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.51) EPS. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on ALNY. Barclays reduced their target price on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research report on Monday, August 3rd. JPMorgan Chase & Co. cut their price objective on shares of Alnylam Pharmaceuticals from $400.00 to $375.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 31st. Stifel Nicolaus lowered their target price on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating on the stock in a report on Friday, July 31st. Finally, HC Wainwright restated a “buy” rating and issued a $455.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $386.14.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.